drugset / Trial / NCT03797066
ATTIC - Access To Treat in the Community
Phase 4
Terminated
13 enrolled
King's College Hospital NHS Trust
Hepatitis C Trust · collabMerck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The study is looking at the potential of utilizing a "point of care" test and treat pathway; using the DDA called Zepatier for achieving SVR in an homeless population who have tested positive for genotype 1 or 4 HCV.
Timeline
- Start
- 2019-03-23
- Primary completion
- 2020-07-28
- Completion
- 2020-11-30
Outcome
Outcome not reported
Stopped (Enrollment): “Changing parameters in HCV management, resulted in poor recruitment; additionally onset of SARS CoV2 resulted in the cessation of all mobile clinical services.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elbasvir | Small molecule | 50 mg | Oral |
| Subject | GRAZOPREVIR ANHYDROUS | Small molecule | 100 mg | Oral |